

# Pharmacy BULLETIN BOARD

Industry Issue ■ Monday June 22, 2015

Odan Laboratories is pleased to introduce their new sodium chloride product:

## ODAN-SODIUM CHLORIDE

### OPHTHALMIC OINTMENT USP

Odan-Sodium Chloride™ ophthalmic ointment is indicated for the temporary relief of corneal edema

The only equivalent to Muro-128<sup>†</sup>

Product	Format	Odan	K & F	McKesson
Odan-Sodium Chloride Ointment NPN 80046696	3.5 g	12735	149285	067490
Odan-Sodium Chloride Solution* NPN 80046737	15 mL	12515	149153	067456

\*Covered by the British-Columbia formulary

To order, please contact your wholesaler or contact Odan directly by phone at 1-800-387-9342 or by e-mail at [info@odanlab.com](mailto:info@odanlab.com).



\*Odan Laboratories Ltd., Montreal, QC, Canada H9R 2Y6

<sup>†</sup>Muro 128 is a registered trademark of Bausch & Lomb

### FROM THE NEWSWIRE

**NORWALK, Conn.:** Mederi Therapeutics Inc. has announced that the American Society for Gastrointestinal Endoscopy (ASGE) has issued new Guidelines that cite Stretta as a viable treatment option for GERD. According to the Guidelines, Stretta was seen as safe, effective and durable, specifically stating: "Adverse events were infrequent and typically minor. The technique appears to durably relieve GERD symptoms for up to 10 years in the majority of patients." The document was prepared by the ASGE Standards of Practice Committee, approved by the ASGE Governing Board, and published in the June issue of Gastrointestinal Endoscopy.

**MISSISSAUGA, ON:** There is a significant disconnect—or gap—between how healthy Canadians think they are and their actual nutritional habits and knowledge. For example, while fruits and vegetables should make up the biggest portion of a healthy diet, well above caffeine, Canadians' daily caffeine consumption is actually on par with their daily fruit and vegetable consumption.



Lower Cost Generic Alternative to Pennsaid®<sup>1</sup>!!!

<sup>P</sup>Taro-Diclofenac

Diclofenac Sodium Topical Solution 1.5%

**Taro-Diclofenac Topical Solution 1.5%** is Available for Immediate Shipping!!!

- Bioequivalent to Pennsaid®<sup>1</sup>
- Interchangeable with Pennsaid (OFI) in Ontario
- High Quality, Lower Price Alternative

Topical Solution 1.5%

DIN	Size	UPC	Wholesaler			
			McKesson	K&F	Procurity	McMahon
02420988	2 x 60 mL	063691073517	060770	147411	256323	10071421
	150 mL	063691073548	060771	147409	256480	10071400

For more information, or to place an order for Taro-Diclofenac topical solution, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975** or visit our website at [www.taro.ca](http://www.taro.ca).

<sup>1</sup>Data on file, Taro Pharmaceuticals Inc.

<sup>2</sup><sup>P</sup>Taro-Diclofenac Product Monograph.

<sup>®</sup>Pennsaid is a registered trademark of Nuvo Research Inc.

Taro is a registered trademark of Taro Pharmaceuticals Inc.

**OTTAWA:** Health Canada and the Federal-Provincial-Territorial Committee on Drinking Water are updating advice for parents of young infants when it comes to using tap water to prepare powdered infant formula during blue-green algal blooms.

**DORVAL, QC:** Novartis announced Cosentyx™ (secukinumab) met the primary endpoints in two new clinical studies, showed superior efficacy compared to placebo in patients with psoriasis of the palms, soles and nails, all difficult-to-treat locations of plaque psoriasis. Detailed findings were presented for the first time at the 23rd World Congress of Dermatology (WCD) in Vancouver, Canada.

**KIRKLAND, QC:** Merck Canada Inc. has announced that KEYTRUDA™ (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada. Among the different types of skin cancer, melanoma has the greatest metastatic potential.



**Lower Cost Generic Alternative to Andriol®<sup>1</sup>**

**◆Taro-Testosterone**

Testosterone Undecanoate Capsules 40 mg

- Bioequivalent and Interchangeable with Andriol®<sup>1</sup>
- High Quality, Lower Price Alternative
- Androgen; testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone<sup>2</sup>

**DIN: 02421186**

Size	UPC	Wholesaler			
		McKesson	K&F	Procurity	McMahon
60	063691075252	071138	149748	010324	10074980
120	063691073333	071136	149837	009946	10075001

For more information, or to place an order for ◆Taro-Testosterone, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our website at [www.taro.ca](http://www.taro.ca).

<sup>1</sup>Data on file, Taro Pharmaceuticals Inc.

<sup>2</sup>◆Taro-Testosterone Product Monograph.

<sup>®</sup>Registered Trademark of N.V. Organon. used under license.

Taro is a registered trademark of Taro Pharmaceuticals Inc.

**DORVAL, QC:** Novartis announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS). Data from the study demonstrated that approximately 74% of patients achieved clinically significant improvement in their symptoms after one year of treatment, as measured by ASAS20, a standard tool used to assess clinical improvement in AS. Detailed study results were presented at the European League Against Rheumatism 2015 Annual Scientific Meeting (EULAR), in Rome, Italy. The safety and efficacy of investigational secukinumab are still under review for AS and market authorization has not been obtained.

**MONTREAL:** Sanofi-aventis Canada Inc. (Sanofi Canada) is taking the precautionary measure of issuing a Voluntary Recall of Allerject 0.15 mg / 0.15 mL epinephrine auto injectors, lots 2857505 and 2857508, distributed as of June 1st, 2015, due to a manufacturing defect potentially affecting the delivery of the drug. This defect was discovered as part of a routine manufacturer quality review process. Allerject 0.15 mg / 0.15 mL is the pediatric version of the epinephrine auto injector. No other lots or strengths of Allerject, or any other Sanofi Canada products are included in this recall. The lots subject to the recall were distributed solely in Canada. There have been no reports of patients adversely affected by the 2 lots distributed to date.

**OTTAWA:** Health Canada has requested that Canadian importers voluntarily quarantine drug products with active pharmaceutical ingredients (APIs) manufactured or tested by Zhejiang Hisun Pharma Company Ltd., in Zhejiang, China, due to data integrity concerns.

**To include your communication in the next issue,  
please contact: Health Response**

T: 416-863-5403 | F: 416-863-9620 |  
[hrc@healthresponse.ca](mailto:hrc@healthresponse.ca)

**Next Issue: Monday July 6<sup>th</sup>, 2015**  
Deadline: Thursday July 2<sup>nd</sup>, 2015